4 / 7
Page 12
Notes:
allied
academies
Archives of General Internal Medicine | Volume 2
&
April 04-05, 2018 | Miami, USA
International Conference on
Internal Medicine & Practice and Primary Care
International Meeting on
Breast Pathology & Cancer Diagnosis
R
ecent studies have suggested that regular intake of
some non-steroidal anti-inflammatory drugs (NSAIDs)
have a preventative effect against several types of tumours
including breast cancer in humans. This work aims to study
the effect of both ibuprofen and aspirin on DNA damage
using lymphocytes obtained from breast cancer patients and
comparing the result with lymphocytes from healthy females
as a control. Lymphocytes are useful surrogates for cancer
cells. Nanoparticles (NPs) and bulk sizes were used in the
comet and micronucleus assays. 250 mg/ml of ibuprofen (NPs
and bulk) and 500 mg/ml of aspirin were used as non-toxic
doses to treat the lymphocytes. Aspirin, both bulk and nano
sizes, showed a significant reduction in DNA damage in the
comet and micronucleus assays. However, the effect of aspirin
nano (P≤0.01) was more significant compared to aspirin bulk
(P≤0.05). Ibuprofen, in contrast, showed a significant reduction
in micronucleus (MNi) frequency in the micronucleus assay
with the nano form (P≤0.001) being more significant than the
bulk form (P≤0.01), whilst its preventative effect with the comet
assay was insignificant. These observations suggest that NPs
have better penetration through the nuclear membrane due to
their smaller size compared to their bulk size. Aspirin was more
effective than ibuprofen in the reduction of DNA damage and
MNi formation in the comet andmicronucleus assays. NPs were
more effective than bulk sizes. The results are consistent with
the view that NSAIDs, particularly aspirin and ibuprofen, could
have a promising role in cancer treatment including breast
cancer.
Speaker Biography
Diana Anderson currently holds the Established Chair of Biomedical Sciences at the
University of Bradford, UK. She obtained her first degree in the University of Wales and
second degrees in the Faculty of Medicine, University of Manchester. After tutoring at
the University of Sydney, Australia, she became a research worker in the Department
of Cancer Studies at the University of Leeds and at the Paterson Laboratories, Christie
Hospital, Manchester. In 1974, she was appointed as Head of Mutagenesis Studies at
ICI’s Central Toxicology Laboratory. She joined BIBRA International in 1981 as Head
of Genetic and Reproductive Toxicology and became Assistant Director and Group
Forum Co-ordinator in 1987. In 1992, she became Senior Associate and Co-ordinator
of External Affairs at BIBRA. In 2011, she won a prize as an Enterprise Fellow from
Yorkshire Forward. In 2015, she won the Vice Chancellor’s award at the University of
Bradford for Outstanding Achievement.
e:
d.anderson1@bradford.ac.ukDiana Anderson
University of Bradford, UK
Comparison of aspirin and ibuprofen bulk and nano forms in peripheral lymphocytes
from breast cancer patients and healthy individuals